Paris, France, 28 August: The echocardiographic response (reduction of left ventricular end-systolic volume) evaluated at 6 months follow-up, demonstrated to be a better predictor of long-term mortality than improvement in clinical status in a large population of CRT patients. Therefore, assessment of occurrence of left ventricular reverse remodeling at mid-term follow-up may be an adequate surrogate end point in heart failure patients treated with CRT.
The efficacy of cardiac resynchronization therapy (CRT) has been demonstrated with significant reductions in mortality and morbidity of heart failure patients. However, many studies have evaluated the efficacy of CRT by means of improvement in heart failure symptoms (clinical response) or reduction in left ventricular volumes (left ventricular reverse remodeling) and improvement in left ventricular function (echocardiographic response) at mid-term follow-up (3 or 6 months after CRT implantation). Based on these surrogate end points, the efficacy of CRT may change significantly and, consequentially, definition of response to CRT is still debated. Ideally, these surrogate end points should determine a significant reduction in mortality. Accordingly, the present evaluation investigated which definition of CRT response at mid-term follow-up (clinical improvement or left ventricular reverse remodeling) best predicts long-term mortality.
A total of 663 advanced heart failure patients were followed-up for the occurrence of all-cause mortality. At 6 months follow-up, the clinical and echocardiographic responses to CRT were evaluated. Clinical response to CRT was defined as a reduction in New York Heart Association functional class of at least 1 point whereas echocardiographic response to CRT was defined by a reduction in left ventricular end-systolic volume of at least 15%. Based on these definitions, 510 (77%) patients showed clinical response and 412 (62%) patients showed echocardiographic response to CRT. During a mean follow-up of 37±22 months, 140 (21%) patients died. Clinical and echocardiographic CRT responses were both significantly related to all-cause mortality. However, only echocardiographic response to CRT was independently associated with a superior survival. In particular, a patient who did not show echocardiographic response had a risk of death three times higher than a patient showing a good echocardiographic response (hazard ratio 0.38; 95% confidence intervals,0.27-0.50; p<0.001).
The Figure shows the probability of all-cause mortality which differed significantly between the 2 groups dichotomized based on the echocardiographic response (left ventricular reverse remodeling). A cumulative 1%, 4% and 8% of the patients with LV reverse remodeling died by 12, 24 and 36 months follow-up, respectively. In contrast, a respective 8%, 19% and 27% of the patients without LV reverse remodeling died during the same time period (log-rank p <0.001).
The present findings have important implications in the design process of clinical trials, since the use of biological markers in the prevention and progression of heart failure (such as changes in left ventricular volumes and function) allow investigators to make a prompt evaluation of heart failure therapies and help to understand the biologic processes underlying the disease and the mechanisms of the therapy. In addition, the use of these surrogate end points permits smaller sample size, shorter trial duration and reduced costs.
In conclusion, the echocardiographic response (reduction of left ventricular end-systolic volume) evaluated at 6 months follow-up demonstrated to be a better predictor of long-term mortality than improvement in clinical status in a large population of CRT patients. Therefore, assessment of occurrence of left ventricular reverse remodeling at mid-term follow-up may be an adequate surrogate end point in heart failure patients treated with CRT.
Contributors: Matteo Bertini; Arnold CT Ng; Dominique Auger; Rutger J. van Bommel; Gaetano Nucifora; Miriam Shanks; C. Jan Willem Borleffs; Eva P.M. van Rijnsoever; Martin J. Schalij; Jeroen J. Bax; Victoria Delgado.
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2011. Impact of clinical and echocardiographic response to cardiac resynchronization therapy on long-term survival The press release has been written by the investigator and edited by the ESC and does not necessarily reflect the opinion of the European Society of Cardiology.
About the European Society of Cardiology The European Society of Cardiology (ESC) represents more than 68,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2011 ESC Congress 2011 will take place from 27 to 31 August at the Parc des Expositions - Paris Nord Villepinte, France. Information on the scientific programme is available here. More information on ESC Congress 2011 is available from the ESC Press Office or contact us at firstname.lastname@example.org
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved